Company Filing History:
Years Active: 1996
Title: Hans P. Leinenbach: Innovator in Cytostatic Combinations
Introduction
Hans P. Leinenbach is a notable inventor based in Munich, Germany. He has made significant contributions to the field of therapeutic procedures through his innovative work on cytostatic and cytotoxic combinations of active substances. His research focuses on enhancing the efficacy of cancer treatments.
Latest Patents
Leinenbach holds a patent for a "Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures." This invention involves a combination of at least one cytostatic compound, such as vincristine, methotrexate, or cisplatin, as the first agent. The second agent consists of at least one histone or an active histone fragment with cytostatic or cytotoxic activity. Both active agents work synergistically at the site of the pathogenic process, potentially improving treatment outcomes.
Career Highlights
Leinenbach's career is marked by his dedication to research and development in the medical field. He has been instrumental in advancing therapeutic strategies that leverage the synergistic effects of various compounds. His work has implications for improving cancer treatment protocols and patient care.
Collaborations
Leinenbach collaborates with Michael Zeppezauer, contributing to the innovative research environment at Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der. Their partnership enhances the development of new therapeutic solutions.
Conclusion
Hans P. Leinenbach's contributions to the field of cytostatic combinations represent a significant advancement in cancer therapy. His innovative approach and collaborative efforts continue to pave the way for improved treatment options.